Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans.

Scott Weir,Robyn Wood,Michael Baltezor,Greg Reed,Amanda E. Brinker,Tammy Ham,Karl Schorno,Paul Toren,Prabhu Ramamoorthy,Valentina Zhukova-Harrill,Michael Dalton,William McCulloch,Manish R. Patel,Susanna Varkey Ulahannan,Howard A. Burris,Gerald Steven Falchook,Roy A. Jensen,Shrikant Anant,John A. Taylor

Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans.

2019

Scott Weir
Robyn Wood
Michael Baltezor
Greg Reed
Amanda E. Brinker
Tammy Ham
Karl Schorno
Paul Toren
Prabhu Ramamoorthy
Valentina Zhukova-Harrill
Michael Dalton
William McCulloch
Manish R. Patel
Susanna Varkey Ulahannan
Howard A. Burris
Gerald Steven Falchook
Roy A. Jensen
Shrikant Anant
John A. Taylor

e14705Background: Ciclopirox Prodrug (CPX-POM) is a novel anticancer agent currently being evaluated in patients with advanced solid tumors participating in a First-in-Human, Phase 1 safety, dose t...

Keywords:

Ciclopirox
Pathology
Pharmacology
Bladder cancer
Prodrug
Pharmacokinetics
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations